TauRx Pharmaceuticals
Total Raised
$212MInvestors Count
3Funding, Valuation & Revenue
7 Fundings
TauRx Pharmaceuticals has raised $212M over 7 rounds.
TauRx Pharmaceuticals's latest funding round was a Option/Warrant - II for $119M on November 14, 2022.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
11/14/2022 | Option/Warrant - II | $119M | Undisclosed Investors | 2 | ||
1/1/2021 | Option/Warrant | |||||
10/8/2015 | Unattributed - II | |||||
3/5/2013 | Corporate Minority - II | |||||
11/20/2012 | Corporate Minority |
Date | 11/14/2022 | 1/1/2021 | 10/8/2015 | 3/5/2013 | 11/20/2012 |
|---|---|---|---|---|---|
Round | Option/Warrant - II | Option/Warrant | Unattributed - II | Corporate Minority - II | Corporate Minority |
Amount | $119M | ||||
Investors | Undisclosed Investors | ||||
Valuation | |||||
Revenue | |||||
Sources | 2 |
TauRx Pharmaceuticals Investors
3 Investors
TauRx Pharmaceuticals has 3 investors. Dundee invested in TauRx Pharmaceuticals's Corporate Minority - II funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
3/5/2013 | 3/5/2013 | 1 Corporate Minority - II | Asset/Investment Management | Canada | ||
Corporation | Malaysia | |||||
Academic/University | United Kingdom |
First funding | 3/5/2013 | ||
|---|---|---|---|
Last Funding | 3/5/2013 | ||
Investor | |||
Rounds | 1 Corporate Minority - II | ||
Board Seats | |||
Type | Asset/Investment Management | Corporation | Academic/University |
Location | Canada | Malaysia | United Kingdom |
Compare TauRx Pharmaceuticals to Competitors
Sumitomo Pharma is a biopharmaceutical company focused on developing therapeutic and scientific breakthroughs. The company's main offerings include the development of novel cancer therapeutics and a robust pipeline of treatments aimed at addressing unmet clinical needs in oncology. Sumitomo Pharma was formerly known as Sumitomo Dainippon Pharma. It was founded in 1897 and is based in Osaka, Japan.
Johnson & Johnson Innovative Medicine focuses on the development and manufacturing of pharmaceutical products. The company offers a range of medicines aimed at treating complex diseases in areas such as cardiovascular and metabolism, immunology, infectious diseases and vaccines, neuroscience, oncology, and pulmonary arterial hypertension. It collaborates globally, engaging in research and development to bring transformative therapies to patients. It was formerly known as Janssen Pharmaceuticals. It was founded in 1953 and is based in Raritan, New Jersey. In October 2010, Janssen Pharmaceuticals was acquired by Johnson & Johnson at a valuation of $2.4B.
Daiichi Sankyo France operates as a global pharmaceutical company with a focus on providing therapeutic solutions in oncology and cardiology. The company offers treatments for various diseases including hypertension, dyslipidemia, diabetes, acute coronary syndrome, venous thromboembolism, breast cancer, metastatic melanoma, inflammatory diseases, and pain. Daiichi Sankyo France primarily serves the healthcare sector, providing innovative medications and supporting services to patients and medical professionals. It was founded in 2003 and is based in Rueil-Malmaison, France.
Cerba HealthCare provides medical diagnostics within the healthcare sector. It offers diagnostic services including proximity biology, specialty biology, clinical trial biology, anatomical and cytological pathology, medical imaging, and preventive biology. These services are used for the diagnosis and management of diseases. It was founded in 1967 and is based in Issy-les-Moulineaux, France.
LifeArc operates as a self-financing medical research charity. The organization specializes in drug discovery, diagnostics development, antibody humanization, and intellectual property management, aiming to lab-based scientific discoveries into diagnostics, treatments, and cures. LifeArc collaborates with various sectors including the pharmaceutical industry, biotechnology sector, and academic institutions to develop and commercialize medical research. LifeArc was formerly known as MRC Technology. It was founded in 2000 and is based in London, United Kingdom.
Servier operates as a global pharmaceutical group focusing on therapeutic advancements in the healthcare sector. The company specializes in developing treatments for cardiometabolism, oncology, and neurology. Servier also produces a range of generic drugs and maintains a focus on patient needs throughout various stages of the medicine life cycle. It was founded in 1954 and is based in Suresnes, France.
Loading...